title: Evaluation of an ex vivo murine local lymph node assay: multiple endpoint comparison.
abstract: The local lymph node assay (LLNA) is used to assess the skin sensitization potential of chemicals. In the standard assay, mice are treated topically on the dorsum of both ears with test substance for 3 days. Following 2 days of rest, the initiation of the hypersensitivity response is evaluated by injecting (3)H-thymidine into a tail vein, and then measuring the levels of radioisotope incorporated into the DNA of lymph node cells draining the ears. In the current study, BALB/c mice were treated with the contact sensitizers hexylcinnamic aldehyde (HCA) and oxazolone, and the nonsensitizer methyl salicylate. The proliferative response of lymph node cells was evaluated in an ex vivo assay, in which isolated cells were cultured in vitro with (3)H-thymidine. Treatment of mice with HCA at 5-50% resulted in concentration-related increases in (3)H-thymidine incorporation, with stimulation indices ranging from 3 to 14. Low animal-to-animal variability was seen in three replicate assays testing HCA at 25%. As anticipated, the proliferative response induced by the potent sensitizer oxazolone at 0.25% was greater than HCA at all concentrations tested. Stimulation indices of 1.5 and 3 were seen in two independent experiments with methyl salicylate. These equivocal findings were likely due to the irritancy properties of the compound. Importantly, measuring ex vivo (3)H-thymidine incorporation was more sensitive than evaluating lymph node weight and cellularity, and in vitro bromodeoxyuridine incorporation. Furthermore, the results of the ex vivo LLNA were comparable to the standard assay. This study provided evidence that supports the use of an ex vivo LLNA for hazard assessment of contact hypersensitivity.
authors.affiliation: Worldwide Safety Sciences, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. joseph.piccotti@pfizer.com
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Piccotti
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Knight
authors.forename: Kimberly
authors.initials: K
authors.lastname: Gillhouse
authors.forename: Mark S
authors.initials: MS
authors.lastname: Lagattuta
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bleavins
mesh_terms: D000171:Acrolein / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000633:toxicity; D000287:Administration, Topical; D000818:Animals; D001973:Bromodeoxyuridine; D049109:Cell Proliferation; D002478:Cells, Cultured; D003877:Dermatitis, Contact / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D023381:Endpoint Determination / Q000379:methods; D005260:Female; D007509:Irritants / Q000008:administration & dosage / Q000633:toxicity*; D023441:Local Lymph Node Assay; D008198:Lymph Nodes / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size; D010081:Oxazolone / Q000008:administration & dosage / Q000633:toxicity; D015203:Reproducibility of Results; D012459:Salicylates / Q000008:administration & dosage / Q000633:toxicity; D013936:Thymidine
chemical_list: D007509:Irritants; D012459:Salicylates; C080043:hexyl cinnamic aldehyde; D010081:Oxazolone; D000171:Acrolein; D001973:Bromodeoxyuridine; C033069:methyl salicylate; D013936:Thymidine